Abstract
Limited information is available regarding the effects of long-acting insulin. We compared the variation in the blood glucose levels between patients treated with insulin degludec (degludec) and those treated with insulin glargine (glargine) using continuous glucose monitoring (CGM). Sixteen patients with type 2 diabetes mellitus were randomly allocated to groups who received either degludec then glargine or vice versa. The patients were hospitalized one month after the start of each drug, and CGM was performed in order to evaluate the differences in glucose variability. Identical test meals were given to all patients during hospitalization. The M-value (0: 00 to 08: 00 (90 mg/dl) ), mean glucose level (0: 00 to 08: 00), SD (0: 00 to 08: 00) and fasting blood glucose level (breakfast) were significantly lower in the patients who received degludec than in those who received glargine (P=0.005, P=0.007, P=0.03, P=0.001, respectively). These results suggest that degludec exerts a more stabilized and potent effect than glargine on glycemic control from night to morning.
